9 Things to Know About Menopause-Related Migraine With Aura and Stroke Risk
Finding out that migraine with aura changes your HRT options is genuinely shocking when nobody mentioned it at the appointment where you were handed a prescription. A lot of women only discover this because they asked the right question at the right time — or because something went wrong. You deserve to know this before it matters urgently.
Learn more about Rose →Migraine With Aura Is Itself a Cardiovascular Risk Factor — Independent of Everything Else
Large meta-analyses confirm that women who experience migraine with aura have approximately twice the risk of ischaemic stroke compared to women without migraine, even after controlling for smoking, blood pressure, and oral contraceptive use. The aura component specifically — not migraine without aura — is what drives this elevated risk, and the mechanism is thought to involve cortical spreading depression, endothelial dysfunction, and hypercoagulability. This is a baseline risk that exists before perimenopause adds its own layer of hormonal and vascular change.
Perimenopause Makes Migraine With Aura More Frequent for Many Women
The erratic oestrogen swings of perimenopause — not simply low oestrogen — are strongly associated with increased migraine frequency, and this is particularly pronounced in women who already have aura. Oestrogen fluctuations affect serotonin pathways, trigeminovascular activity, and prostaglandin release, all of which feed into migraine generation. Women who previously had manageable or infrequent aura episodes often find they escalate significantly in the two to five years before their final period.
Combined Oral Contraceptives Are Generally Not Recommended for Women With Migraine With Aura
The combined oral contraceptive pill, which contains both synthetic oestrogen and progestogen, is typically contraindicated in women with migraine with aura because it raises stroke risk substantially when layered on top of the aura-related baseline. This guidance comes from bodies including the WHO and the Faculty of Sexual and Reproductive Healthcare and is graded as a Category 4 risk — meaning risks outweigh benefits — for this specific combination. Women in perimenopause who are still using the pill for contraception or cycle management need to have this conversation explicitly with their clinician.
Transdermal HRT Has a Significantly Different Risk Profile Than Oral HRT
Oral oestrogen is metabolised through the liver, which increases clotting factors and raises the risk of venous thromboembolism and potentially stroke — a concern that matters more in women who already carry aura-related risk. Transdermal oestrogen, delivered via patches, gels, or sprays, bypasses first-pass liver metabolism and does not appear to increase clotting factor production in the same way. Observational data consistently show that transdermal oestrogen does not carry the same elevated thrombotic risk as oral forms, making it the preferred route for women with migraine with aura who are considering HRT.
Stable Oestrogen Levels May Actually Reduce Migraine Frequency After the Transition
While perimenopause — with its chaotic hormonal fluctuations — often worsens migraine with aura, postmenopause brings more stable (if low) oestrogen levels, and many women find their migraine frequency decreases after their final period. Some evidence suggests that maintaining steady oestrogen levels through transdermal HRT can replicate this stabilising effect and reduce fluctuation-driven attacks during the transition. The goal with HRT in this context is hormonal steadiness, not high doses — peaks and troughs in oestrogen are more likely to trigger aura than a consistent background level.
Smoking Turns This Risk Combination Into Something Clinicians Take Very Seriously
Smoking independently multiplies stroke risk, and when combined with migraine with aura, the interaction is not simply additive — some data suggest the combined risk is multiplicative, pushing ischaemic stroke odds to levels that prompt most guidelines to recommend urgent cessation and careful reassessment of all hormonal treatment. Women who smoke and have migraine with aura are generally considered high-risk candidates for any oestrogen-containing therapy. Stopping smoking is one of the highest-impact actions available to this specific group.
A New Onset of Aura in Midlife Warrants Medical Evaluation Before Attributing It to Perimenopause
When aura symptoms appear for the first time in perimenopause — particularly visual disturbances, unilateral numbness, or speech changes — they should be assessed by a clinician to rule out transient ischaemic attack or other neurological causes before being attributed to migraine. The two conditions can look similar, especially in women who have never experienced aura before, and assuming a vascular event is a migraine can delay critical intervention. New neurological symptoms in midlife always deserve investigation first.
Progestogen Type in HRT May Also Matter for Migraine Frequency
Synthetic progestogens, particularly norethisterone and levonorgestrel, are associated with higher rates of migraine aggravation than body-identical progesterone (micronised progesterone) in some women, possibly because of their androgenic and anti-oestrogenic properties. Micronised progesterone has a more favourable neurological profile and is increasingly preferred in women whose migraines are sensitive to hormonal change. Discussing progestogen choice — not just oestrogen route — is a relevant part of tailoring HRT for women with migraine with aura.
This Risk Profile Requires a Joined-Up Conversation Between a Menopause Clinician and a Neurologist or GP With Both Specialisms
The intersection of migraine with aura, perimenopause, and stroke risk sits uncomfortably between specialities — neurologists manage the migraine, menopause clinicians manage the hormones, and neither always has the full picture. Women in this group benefit most from a single clinician who understands both, or from active coordination between their care providers, particularly before starting or changing HRT. Bringing written documentation of migraine frequency, aura type, and cardiovascular history to appointments significantly improves the quality of the conversation.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.